These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

849 related articles for article (PubMed ID: 35757764)

  • 21. Comparison of the reactogenicity and immunogenicity between two-dose mRNA COVID-19 vaccine and inactivated COVID-19 vaccine followed by an mRNA vaccine in children aged 5-11 years.
    Wanlapakorn N; Kanokudom S; Phowatthanasathian H; Chansaenroj J; Suntronwong N; Assawakosri S; Yorsaeng R; Nilyanimit P; Vichaiwattana P; Klinfueng S; Thongmee T; Aeemjinda R; Khanarat N; Srimuan D; Thatsanatorn T; Chantima W; Pakchotanon P; Duangchinda T; Sudhinaraset N; Poovorawan Y
    J Med Virol; 2023 May; 95(5):e28758. PubMed ID: 37212319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody Fc receptor binding and T cell responses to homologous and heterologous immunization with inactivated or mRNA vaccines against SARS-CoV-2.
    Cohen CA; Leung NHL; Kaewpreedee P; Lee KWK; Jia JZ; Cheung AWL; Cheng SMS; Mori M; Ip DKM; Poon LLM; Peiris JSM; Cowling BJ; Valkenburg SA
    Nat Commun; 2024 Aug; 15(1):7358. PubMed ID: 39191745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine.
    Yavuz E; Günal Ö; Başbulut E; Şen A
    J Med Virol; 2022 Aug; 94(8):3768-3775. PubMed ID: 35434796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up.
    Salehi M; Alavi Darazam I; Nematollahi A; Alimohammadi M; Pouya S; Alimohammadi R; Khajavirad N; Porgoo M; Sedghi M; Mahdi Sepahi M; Azimi M; Hosseini H; Mahmoud Hashemi S; Dehghanizadeh S; Khoddami V
    Int Immunopharmacol; 2024 Jun; 134():112192. PubMed ID: 38761778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naïve and previously infected individuals.
    Muena NA; García-Salum T; Pardo-Roa C; Avendaño MJ; Serrano EF; Levican J; Almonacid LI; Valenzuela G; Poblete E; Strohmeier S; Salinas E; Muñoz A; Haslwanter D; Dieterle ME; Jangra RK; Chandran K; González C; Riquelme A; Krammer F; Tischler ND; Medina RA
    EBioMedicine; 2022 Apr; 78():103972. PubMed ID: 35366624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interchangeability of different COVID-19 vaccine platforms as booster doses: A phase 3 study mimicking real-world practice.
    Ann Costa Clemens S; Weckx L; Milan EP; Smolenov I; Clemens R
    Vaccine; 2024 Jul; 42(19):3989-3998. PubMed ID: 38762360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial.
    Li J; Hou L; Guo X; Jin P; Wu S; Zhu J; Pan H; Wang X; Song Z; Wan J; Cui L; Li J; Chen Y; Wang X; Jin L; Liu J; Shi F; Xu X; Zhu T; Chen W; Zhu F
    Nat Med; 2022 Feb; 28(2):401-409. PubMed ID: 35087233
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity of Two Doses of BNT162b2 mRNA COVID-19 Vaccine with a ChAdOx1-S Booster Dose among Navy Personnel in Mexico.
    Ventura-Enríquez Y; Cortina-De la Rosa E; Díaz-Padilla E; Murrieta S; Segundo-Martínez S; Fernández-Sánchez V; Vargas-De-León C
    Viruses; 2024 Apr; 16(4):. PubMed ID: 38675894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Humoral immunity against SARS-CoV-2 evoked by heterologous vaccination groups using the CoronaVac (Sinovac) and BNT162b2 (Pfizer/BioNTech) vaccines in Chile.
    Díaz-Dinamarca DA; Díaz P; Barra G; Puentes R; Arata L; Grossolli J; Riveros-Rodriguez B; Ardiles L; Santelises J; Vasquez-Saez V; Escobar DF; Soto D; Canales C; Díaz J; Lamperti L; Castillo D; Urra M; Zuñiga F; Ormazabal V; Nova-Lamperti E; Benítez R; Rivera A; Cortes CP; Valenzuela MT; García-Escorza HE; Vasquez AE
    Front Public Health; 2023; 11():1229045. PubMed ID: 37693706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection.
    Suah JL; Tng BH; Tok PSK; Husin M; Thevananthan T; Peariasamy KM; Sivasampu S
    Emerg Microbes Infect; 2022 Dec; 11(1):1343-1345. PubMed ID: 35499301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.
    Jara A; Undurraga EA; Zubizarreta JR; González C; Pizarro A; Acevedo J; Leo K; Paredes F; Bralic T; Vergara V; Mosso M; Leon F; Parot I; Leighton P; Suárez P; Rios JC; García-Escorza H; Araos R
    Lancet Glob Health; 2022 Jun; 10(6):e798-e806. PubMed ID: 35472300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern.
    Schultz BM; Melo-González F; Duarte LF; Gálvez NMS; Pacheco GA; Soto JA; Berríos-Rojas RV; González LA; Moreno-Tapia D; Rivera-Pérez D; Ríos M; Vázquez Y; Hoppe-Elsholz G; Andrade-Parra CA; Vallejos OP; Piña-Iturbe A; Iturriaga C; Urzua M; Navarrete MS; Rojas Á; Fasce R; Fernández J; Mora J; Ramírez E; Gaete-Argel A; Acevedo ML; Valiente-Echeverría F; Soto-Rifo R; Weiskopf D; Grifoni A; Sette A; Zeng G; Meng W; ; González-Aramundiz JV; González PA; Abarca K; Kalergis AM; Bueno SM
    mBio; 2022 Aug; 13(4):e0142322. PubMed ID: 35946814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of vaccine booster, vaccine type, and hybrid immunity on humoral and cellular immunity against SARS-CoV-2 ancestral strain and Omicron variant sublineages BA.2 and BA.5 among older adults with comorbidities: a cross sectional study.
    Fong CH; Zhang X; Chen LL; Poon RW; Chan BP; Zhao Y; Wong CK; Chan KH; Yuen KY; Hung IF; Yuen JKY; To KK
    EBioMedicine; 2023 Feb; 88():104446. PubMed ID: 36706582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of different booster vaccine combinations against SARS-CoV-2 during a six-month follow-up in Mexico and Argentina.
    Garza-Silva A; Rivera-Salinas D; Rivera-Cavazos A; Fernández-Chau IF; Cepeda-Medina AB; Morales-Rodríguez DP; Barco-Flores IA; Sanz-Sánchez MÁ; Acciardi C; Paez-Bo G; Teixeira MM; Azzolini E; Pozzi C; Rescigno M; Romero-Ibarguengoitia ME
    Front Immunol; 2024; 15():1403784. PubMed ID: 38807602
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2.
    Rammauro F; Carrión F; Olivero-Deibe N; Fló M; Ferreira A; Pritsch O; Bianchi S
    Vaccine; 2022 Aug; 40(35):5189-5196. PubMed ID: 35907676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults.
    Costa Clemens SA; Marchevsky N; Kelly S; Felle S; Eldawi A; Rajasingam R; Mahmud R; Lambe T; Voysey M; Gonzalez I; Milan EP; Justino MC; Bibi S; Aley P; Clemens R; Pollard AJ
    Hum Vaccin Immunother; 2023 Aug; 19(2):2233400. PubMed ID: 37438960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 omicron infection and related hospital admission among people with substance use disorder in Hong Kong: a matched case-control study.
    Huang C; Wei Y; Yan VKC; Ye X; Kang W; Yiu HHE; Shami JJP; Cowling BJ; Tse ML; Castle DJ; Chui CSL; Lai FTT; Li X; Wan EYF; Wong CKH; Hayes JF; Chang WC; Chung AKK; Lau CS; Wong ICK; Chan EW
    Lancet Psychiatry; 2023 Jun; 10(6):403-413. PubMed ID: 37141907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study.
    Mok CKP; Chen C; Zhao S; Sun Y; Yiu K; Chan TO; Lai HL; Lai KC; Lau KM; Ling KC; Chan KKP; Ng SS; Ko FW; Peiris M; Hui DS
    Lancet Microbe; 2023 Jun; 4(6):e418-e430. PubMed ID: 37086735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and reactogenicity of fractional, heterologous primary COVID-19 vaccination schedules with BNT162b2 boosters in 5-11-year-old Thai children: A multicenter, prospective, double-blind, randomized control trial.
    Wittawatmongkol O; Bunjoungmanee P; Kosalaraksa P; Laoprasopwattana K; Boonsathorn S; Chantasrisawad N; Sudjaritruk T; Niyomnaitham S; Senawong S; Srisutthisamphan K; Quan Toh Z; Rungmaitree S; Nanthapisal S; Phanthanawiboon S; Khantee P; Techasaensiri C; Hirankarn N; Pangprasertkul S; Chokephaibulkit K
    Vaccine; 2023 Sep; 41(40):5834-5840. PubMed ID: 37586956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Booster vaccination using bivalent DS-5670a/b is safe and immunogenic against SARS-CoV-2 variants in children aged 5-11 years: a phase 2/3, randomized, active-controlled study.
    Suzuki R; Suda M; Ishida K; Furihata K; Ota A; Takahashi K; Sakakibara S; Nakayama T; Takeshita F
    Front Immunol; 2024; 15():1445459. PubMed ID: 39286253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.